Summary:
In patients with diabetic foot ulcers (DFUs), oral sitagliptin (100 mg daily) in combination with standard therapy significantly improved ulcer healing rates, reduced ulcer area, and increased CD34+ endothelial progenitor cells and SDF-1α levels compared to standard conventional therapy alone, though it was associated with no reported adverse effects.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetes mellitus presenting with diabetic foot ulcers (DFUs). |
| Intervention | Oral sitagliptin 100 mg once daily added to standard conventional therapy for DFUs. |
| Comparison | Standard conventional therapy alone for diabetic foot ulcers. |
| Outcome | Sitagliptin significantly improved ulcer healing rates (p < 0.05), reduced ulcer area, elevated peripheral blood CD34+ EPCs, and increased SDF-1α levels. There was a trend toward shorter healing time (p = 0.071), with no significant differences in HbA1c or adverse events reported. |
Source: Wei Gao, et al. “Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial.” Read article here.
